New IDEAS

The Alzheimer’s Association Chief Science Officer, Dr. Maria Carillo, and Chief Diversity Equity and Inclusion Officer, Carl V. Hill, discuss the importance of diversity in clinical trials and describe the New IDEAs clinical study.